FDA authorizes lower dose of Regeneron antibody cocktail for COVID-19

964418

Sumary of FDA authorizes lower dose of Regeneron antibody cocktail for COVID-19:

  • The FDA has authorized a lower dose of Regeneron antibody cocktail to treat COVID-19, which the company said may help more patients access the treatment..
  • The updated EUA also allows the cocktail, called REGEN-COV, to be delivered subcutaneously “when IV infusion is not feasible and would lead to a delay in treatment.”.
  • government to treat patients aged 12 years or older with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death..
  • “Despite increased use of vaccines, thousands of patients are still becoming infected in the United States every day, with many at high risk of serious complications from COVID-19..
  • Unfortunately, to date, only a fraction of patients eligible for antibody treatments have received them, which we hope will change based on this updated FDA authorization,”.
  • The updated EUA was based on the results of several trials, including a phase 3 trial that was presented recently at the American Thoracic Society International Conference that demonstrated a consistent treatment effect between the two doses..
  • In its treatment guidelines, the Infectious Diseases Society of America suggests using REGEN-COV or another antibody cocktail containing bamlanivimab and etesevimab to treat ambulatory patients with mild-to-moderate COVID-19 who are at risk for progression to severe disease…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close